RNAi Therapeutics
•24 stocks
•
Total Market Cap: Loading...
Dec 15, 2025
|
Silence Therapeutics CEO Craig Tooman Resigns; Chairman Iain Ross to Serve as Interim CEO
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (24)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
RNAi therapeutics are part of Lilly's genetic medicine push.
|
$972.49B |
$1053.75
+2.55%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
C5 siRNA program represents RNA interference therapeutics in Regeneron’s genetic medicines portfolio.
|
$78.57B |
$751.00
+1.31%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$52.11B |
$394.75
-0.71%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$9.69B |
$68.36
-2.47%
|
|
RNA
Avidity Biosciences, Inc.
RNA interference (siRNA) payloads are part of the therapeutic approach described (AOC delivering RNA-based payloads).
|
$9.24B |
$71.83
-0.01%
|
|
CRSP
CRISPR Therapeutics AG
SRSD107 is an RNA interference therapeutic, aligning with the RNAi Therapeutics category.
|
$5.16B |
$56.60
-0.13%
|
|
APLS
Apellis Pharmaceuticals, Inc.
APLJ? APL-3007 is an siRNA therapeutic targeting FcRn, placing the program under the RNAi Therapeutics theme.
|
$3.19B |
$25.18
-0.18%
|
|
WVE
Wave Life Sciences Ltd.
WVE-007 includes an siRNA (RNA interference) program, making RNAi therapeutics a core modality for the company.
|
$2.64B |
$16.43
-0.79%
|
|
SRPT
Sarepta Therapeutics, Inc.
siRNA platform (TRiM) with Arrowhead collaboration positions Sarepta in RNA interference therapeutics.
|
$2.10B |
$21.30
-1.09%
|
|
AGIO
Agios Pharmaceuticals, Inc.
AG-236 is an siRNA (RNAi) therapeutic in preclinical development, fitting RNAi therapeutics as a major modality in Agios's pipeline.
|
$1.58B |
$26.80
-1.72%
|
|
QURE
uniQure N.V.
miQURE silencing technology enables RNA interference-based therapeutics, placing the company in the RNAi therapeutics modality.
|
$1.07B |
$19.80
+1.51%
|
|
VIR
Vir Biotechnology, Inc.
Elebsiran is an RNA interference (RNAi) therapeutic, placing Vir in RNAi Therapeutics.
|
$929.35M |
$6.71
+0.22%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$902.90M |
$4.83
+2.65%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's RNA interference modality (RNAi therapeutics) aligns with a gene-silencing oligonucleotide approach described in the program.
|
$506.25M |
$10.60
-2.21%
|
|
BNTC
Benitec Biopharma Inc.
Benitec's ddRNAi approach centers on RNA interference therapeutics, placing it under RNAi Therapeutics.
|
$314.48M |
$12.02
+0.33%
|
|
SLN
Silence Therapeutics plc
Silence Therapeutics directly develops RNA interference therapeutics (siRNA) as its core product modality.
|
$298.10M |
$6.48
+2.53%
|
|
VYGR
Voyager Therapeutics, Inc.
VY1706 uses siRNA payload delivered via TRACER capsids, mapping to RNAi Therapeutics.
|
$243.51M |
$4.26
-2.96%
|
|
ALEC
Alector, Inc.
ADP064-ABC includes an anti-tau siRNA program, representing RNA interference therapeutics.
|
$150.81M |
$1.45
-3.02%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$150.75M |
$1.63
-2.40%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$36.57M |
$5.43
+0.09%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-KIT is described as a precision antisense therapy, aligning with RNAi therapeutics.
|
$15.51M |
$1.12
-3.85%
|
|
RNAZ
TransCode Therapeutics, Inc.
Company focuses on RNA interference (RNAi) therapeutics, including siRNA/miRNA-targeted programs.
|
$7.93M |
$9.61
+1.00%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is based on RNA interference (siRNA), making RNAi therapeutics a core product/framework.
|
$6.41M |
$1.11
-0.45%
|
|
RGBP
Regen BioPharma, Inc.
DiffronC is described as an in vivo siRNA therapy, placing RGBP in the RNAi Therapeutics space.
|
$224038 |
$0.01
|
Loading company comparison...
Loading industry trends...
Loading research report...
